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A (GGGGCC)n repeat expansion in C9orf72 gene is the major cause of frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS). The relations between the repeats size and the age at disease onset
(AO) or the clinical phenotype (FTD vs. ALS) were investigated in 125 FTD, ALS, and presymptomatic
carriers. Positive correlations were found between repeats number and the AO (p < 10e4) but our results
suggested that the association was mainly driven by age at collection (p < 10e4). A weaker association
was observed with clinical presentation (p ¼ 0.02), which became nonsignificant after adjustment for the
age at collection in each group. Importantly, repeats number variably expanded or contracted over time
in carriers with multiple blood samples, as well as through generations in parent-offspring pairs,
conversely to what occurs in several expansion diseases with anticipation at the molecular level. Finally,
this study establishes that measure of repeats number in lymphocytes is not a reliable biomarker pre-
dictive of the AO or disease outcome in C9orf72 long expansion carriers.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).a moelle épinière (ICM), AP-
57274682.
Ber), mathieu.barbier@icm-
Inc. This is an open access article u1. Introduction
Frontotemporal dementia (FTD) is the second cause of degener-
ative dementia in the presenium, after Alzheimer’s disease. A familial
history of the disease is reported in half of the patients. Most of the
familial cases reflect a monogenic origin with an autosomalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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C. Fournier et al. / Neurobiology of Aging 74 (2019) 234.e1e234.e8 234.e2dominant mode of inheritance. Symptoms of amyotrophic lateral
sclerosis (ALS) are associated in 15% of patients with FTD. A GGGGCC
(G4C2) repeat expansion in the first intron of chromosome 9 open
reading frame 72 (C9orf72) is one of the major genetic cause of FTD
and of ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Most
healthy individuals carry fewer than 24 repeats, whereas patients
have up to thousands of hexanucleotide copies (DeJesus-Hernandez
et al., 2011; Renton et al., 2011). Threemechanismsmight explain the
pathogenicity of large repeat expansions: a C9orf72 loss-of-function,
the formation of nuclear sense and anti-sense RNA foci, and dipep-
tide repeat proteins generated by repeat-associated non-ATG
translation (Lagier-Tourenne et al., 2013).
C9orf72 disease is characterized by an important heterogeneity
of clinical presentation (FTD, ALS) and of age of disease onset.
Behavioral or motor symptoms can occur from the third decade of
life, to a nearly incomplete penetrance in elderly mutation carriers
(Le Ber et al., 2013). The size of the expansion also greatly varies
among C9orf72 carriers and might explain a part of this clinical
variability, particularly of the age at disease onset (AO) as reported
in other repeat expansion diseases. Few studies have analyzed
C9orf72 expansion sizes in blood, with controversial results
concluding either to a positive (Beck et al., 2013), the absence (Dols-
Icardo et al., 2014; Nordin et al., 2015; van Blitterswijk et al., 2013),
or an inverse correlation with AO (Gijselinck et al., 2016; Van
Mossevelde et al., 2017). Most of these studies were based on a
limited number of C9orf72 carriers, thus precluding definite con-
clusions. Consequently, no clear information about the correlation
of C9orf72 repeats number and clinical phenotypes is available to
date, and further investigations are needed in large cohorts of
patients.
Establishing whether the size of the expansion in blood can be
used as a reliable peripheral marker predicting the age at onset and
disease outcome in mutation carriers is critical when therapeutics
based on antisense oligonucleotides or other molecules are being
developed (Donnelly et al., 2013; Jiang et al., 2016). To address these
questions, we quantified the expansion size of C9orf72 in peripheral
lymphocytes from 125 carriers, which represents the largest cohort
studied so far. The correlations between the expansion size and
clinical phenotype, AO or age at blood collection, and the dynamic
of the expansion in lymphocytes through time and over generations
were analyzed.
2. Material and methods
2.1. Subjects and ethics
The estimate of G4C2 repeats number on the expanded allele was
done in 125 C9orf72 carriers, including 73 symptomatic patients
and 52 presymptomatic (PS) carriers. Genetic status has been
established for all of them by repeat-primed PCR before, as previ-
ously described (Le Ber et al., 2013). Clinical data and blood samples
were obtained after written informed consent for clinic-genetic
studies was signed. Local ethic committee approvals were ob-
tained for studies of symptomatic (IRB: CPP Ile de France II, project
#RBM 02-59) and presymptomatic carriers (RCB: 2015-A00856-43
CPP 68-15 Ile-de-France VI, for PrevDemAls and FTLD-exome
studies, respectively).
A brief description of patients and PS cohorts is provided in
Table 1. Among the patients (62 were French, 11 Italian), 42 pre-
sented isolated FTD, 12 had isolated ALS, and 19 had FTD and
secondarily developed ALS.
Eleven carriers (8 patients, 1 PS, 2 converters) from this cohort
had multiple time points (2e4 times). Time intervals between first
and last blood samples ranged from 7 months to 11 years (mean
interval ¼ 57.9 months; SD ¼ 39.2 months).
C. Fournier et al. / Neurobiology of Aging 74 (2019) 234.e1e234.e8234.e32.2. Molecular analyses and sizing of C9orf72 repeat number by
Southern blot
Genomic DNA was extracted from peripheral lymphocytes.
Southern blots were then performed to size the repeat expansion
(Beck et al., 2013). Briefly, 15 mg of genomic DNA was digested over-
nightwith AluI (20 u) andDdeI (20 u) before electrophoresis. DNAwas
transferred to positively charged nylon membrane (Roche Applied
Science) by capillary blotting and was baked at 80C for 2 hours. The
hybridization probe was an oligonucleotide from Eurofins MWG
Operon (Germany) and comprised 5 hexanucleotide repeats
(GGGGCC)5 labeled 30 and 50 with digoxigenin (DIG). Filter hybridi-
zation was undertaken as recommended in the DIG Application
Manual (Roche Applied Science) except for the supplementation of
DIG Easy Hyb buffer with 100 mg/mL denatured fragmented salmon
sperm DNA. After prehybridization at 48C for 4 hours, hybridization
was allowed to proceed at 48C overnight. A total of 1 ng of labeled
oligonucleotide probe were used per milliliter of hybridization solu-
tion. Membranes were washed initially in 2 standard sodium citrate
(SSC) and 0.1% sodiumdodecyl sulfate (SDS), while the ovenwas being
ramped from 48C to 65C and thenwashed in fresh solution at 65C
for 15 minutes; further 15 minutes washes in 0.5 SSC, 0.1% SDS and
0.2 SSC, and 0.1% SDS at 65C followed. Detection of the hybridized
probe DNA was carried out with Digoxigenin antibodyeHRP (Anti-
bodies-online, 1/10,000 dilution) and reveled with ECL (“SuperSignal
West Dura Extended DurationSubstrate” Fisher Scientific). Signals
were visualized on Fluorescent Detection Film (Roche Applied Sci-
ence) after 1e5 hours. All samples were electrophoresed against DIG-
labeled DNA molecular-weight markers VII (Roche Applied Science).
Hexanucleotide repeats numberwas estimated by visual interpolation
with a plot (created in Microsoft Excel) of log10 base-pair number
against migration distance and subtraction of the wild-type allele
fragment size (199 bp). Mode and mean sizes were recorded for each
individual with expanded repeats as described previously (Suh et al.,
2015). The mode, defined as the point on the Southern blot with the
highest intensity, was used for all the statistical analysis. For patients
with multiple collections, modal number of repeats measured at the
first sampling was used in correlation tests. Six technical duplicates
were used to estimate the range of imprecision when sizing C9orf72
large expansions with this method. DNA extracted from the same
blood collection of 6 patients was used in 2 different Southern blots.
The absolute value of difference between 2 measures ranged from 16
to 172 repeats.
2.3. Comparisons and statistical analyses
Relations between repeats number and AO, age at blood
collection, and clinical phenotype (FTD vs. ALS) were evaluated. We
first investigated the association between repeats number and AO
in patients with extreme AO: early (48 years; n ¼ 23 patients) or
late onset (68 years; n ¼ 25). AO, as well as the age at collection,
was also considered as continuous variables in correlation analyses.
Relations between the age at collection and repeats number were
investigated in both symptomatic and PS carriers.
We also compared repeats number in a subgroup of youngest
patients with an age at onset 45 years (n ¼ 16) and in presymp-
tomatic carriers with an age at the time of blood collection
45 years (n ¼ 32).
To accurately evaluate the impact of the repeats number on the
phenotype, we compared 2 groups of patients: those with isolated
ALS (n ¼ 12) and those with isolated FTD (n ¼ 42); cases presenting
both phenotypes (FTD and ALS) were not included in any group in
this analysis.
Finally, we assessed the dynamic of the expansion in lymphocytes
in a givenpatient over time and over successive generations in familialcases. We evaluated whether the size varied over time in mutation
carriers with multiple sample collections (n ¼ 11) by comparing the
expansion at each time point, regardless of the time interval during
successive time points. The repeat size transmission across genera-
tions was evaluated by studying repeat size in 16 parent-offspring
pairs belonging to 12 families from the whole cohort.
The F-test was used to compare variances of C9orf72 repeat
number between PS and symptomatic patients, as the repeat
number followed a normal distribution in both groups (Kolmo-
gorov-Smirnov normality test p> 0.05). Conversely, the AO and age
at collection did not pass normality tests in our cohort (Kolmo-
gorov-Smirnov normality test p < 0.05). Consequently, Spearman’s
rho (r) was used to estimate correlation levels with associated 2-
tailed p value. A 2-tailed Mann-Whitney U test was performed for
all statistical comparisons of means.
Since a previous study showed that gender can influence AO in
patients with C9orf72 mutations (Le Ber et al., 2013), correlations be-
tween C9orf72 repeats number and AO were calculated using residual
values of AO after adjusting for sex. In some analyses, repeats number
was adjusted for the age at collection or AO. Residual values of repeats
number were then used in correlation or in group comparisons ana-
lyses. GraphPad Prism Software v5.00 was used for data visualization.
3. Results
3.1. Clinical and molecular characteristics of patients and PS
carriers
The mean AO in C9orf72 patients was 58 years (range:
37e77 years; median ¼ 59; SD ¼ 12.0). Although the mean AO was
lower in ALS and FTD-ALS patients than in patients with isolated
FTD, none of these differences was significant between the 3 groups
(p > 0.05 for all comparisons).
The mean age at first blood collection was 45.8 years in PS
(range: 20e88 years; median ¼ 43; SD ¼ 16.7) and 61 years in
symptomatic subjects (range: 39e80 years; median ¼ 62; SD ¼
11.4). The mean age at collection was lower in ALS and FTD-ALS
compared to FTD but, here again, these differences were not sig-
nificant (p > 0.05 for all mean comparisons).
The number of repeats ranged from 1459 to 3889 (mean¼ 2334;
SD ¼ 489.9) in PS carriers and from 1294 to 3320 (mean ¼ 2426,
SD ¼ 480.7) in symptomatic patients. Means and variances of
repeat number did not differ significantly between PS and symp-
tomatic patients (p¼ 0.19 for Mann-Whitney U test and p¼ 0.87 for
F-test). Details of repeat sizes distribution parameters in all carriers’
groups are shown in Table 1 and Supplementary Fig. 1.
3.2. Relations between repeat expansion size, age at onset, and age
at blood collection
Mean repeats number was significantly lower in patients with
early onset (AO 48, mean ¼ 2186) than in patients with late onset
(AO  68, mean ¼ 2741) (p ¼ 0.0001; Fig. 1A). When AO was
considered as a continuous variable, repeats number was positively
correlated with AO (r ¼ 0.54; p < 0.0001) (Fig. 1B).
Relations between age at collection and repeats number were
investigated as well (Fig. 2). We observed similar trends of correla-
tions between repeats number and age at collection in patients (r ¼
0.51; p < 0.0001). Considering that the age at collection might in-
fluence the C9orf72 pathogenic expansion size in blood and could be
a confounding factor in our analyses, repeats number was adjusted
for age at collection and used in statistical analyses. The residual
correlation of repeats number adjusted for age at collection with AO
was no longer significant (r ¼ -0.008; p ¼ 0.95). In the same way,
comparisons of adjusted repeats number for age at collection
Fig. 1. Relations between C9orf72 G4C2 repeats number and clinical features in patients. (A): Comparison of repeat number in early-onset ([EO]; AO  48y; n ¼ 23) and late-onset
([LO]; AO  68y; n ¼ 25). (B): Correlation between repeats number and AO. A regression line is displayed. (C): Comparison of repeats number between FTD (n ¼ 42) and ALS patients
(n ¼ 12). For statistical comparison between 2 groups, mean and standard deviation are displayed in each group. For correlation, Spearman’s r is indicated. For all statistical tests,
asterisks represent p value significance (***p  0.0001; *p < 0.05).
C. Fournier et al. / Neurobiology of Aging 74 (2019) 234.e1e234.e8 234.e4between patients with extreme AO (EO vs. LO) became nonsignifi-
cant (p ¼ 0.84). When repeats number was adjusted for AO, the re-
sidual correlationwas slightly higher (r¼ 0.12) but nonsignificant. As
attempted, AO and age at collection were highly correlated in our
cohort (r ¼ 0.95, p < 0.0001). Importantly, the same trend of cor-
relation was found in PS individuals. The number of G4C2 repeats in
the expanded allele was positively correlated with age at collection
(r ¼ 0.65; p < 0.0001). To go further, we compared the mean size of
expansions in the subgroup of PS carriers with the youngest age at
collection (45 years) and in patients who developed the disease
before 45 years. Means of repeats number were lower in each sub-
group compared to their respective whole cohort of patients and PS
carriers. Difference of means between these 2 subgroups was not
significant (2037 vs. 2147, respectively; p ¼ 0.59).3.3. Relations between repeat number and clinical phenotypes (FTD
vs. ALS) in patients
Mean number of repeats was slightly lower in patients with ALS
versus FTD (2228 vs. 2540, respectively; p ¼ 0.024, Fig. 1C). Com-
parisons of repeats number adjusted for the age at collection be-
tween these 2 groups became nonsignificant (p ¼ 0.33).3.4. Dynamic of the pathogenic expansion in lymphocytes over time
For a subset of the aforementioned samples (n ¼ 11), multiple
time points were available. These patients and PS individuals gave
us the opportunity to measure expansion size changes over time
individually and to evaluate relations with disease onset. We didFig. 2. Correlations between C9orf72 G4C2 repeats number and age at collection in patients (
Asterisks represent p value significance (***p < 0.0001).not detect important repeats number differences or a clear trend
toward expansion or contraction of the pathogenic expansion in the
time intervals considered (Fig. 3). The absolute values of repeat
number differences between collections ranged from 15 to 231.
Among the carriers, 2 patients (patients 8 and 11, Fig. 3) developed
symptoms between 2 blood collection times. These 2 converters did
not present massive expansion or contraction of repeats number
before and after disease onset. Little and opposite changes were
observed for these 2 individuals (-173 repeats andþ56 repeats for a
time interval of 6.5 and 11 years, respectively).3.5. Dynamic of the repeat expansion in parent-offspring
transmissions
A total of 16 parent-offspring transmissions have been studied
from the whole cohort, including 8 simple parent-offspring trans-
missions and 4 parents with 2 children each (Fig. 4). A reduction of
repeats number from parents to children was observed in 11/16
pairs (mean ¼ -503 repeats). Conversely, the repeats number
increased over generations in 4/16 pairs (mean ¼ þ399 repeats).
Nearly the same expansion size was detected in one parent-
offspring pair. Expansion or contraction of repeats number over
generations did not depend on the gender, the age at collection, nor
the age at onset of the transmitting parent (Fig. 4).4. Discussion
The intronic G4C2 pathogenic expansion in C9orf72 is the major
genetic cause of FTD, FTD-ALS, and ALS (Cruts et al., 2013; Le BerA) and in presymptomatic carriers (B). A regression line and Spearman’s r are indicated.
Fig. 3. C9orf72 G4C2 repeats number in carriers with multiple blood collections. Samples are ordered in function of time (1 > 4 when available). Carriers are ordered from the
individual with the shortest to the longest time interval between first and last blood collection. Duration between first and last collection is indicated in month (mo) or years (y)
above repeats number estimates. Patients 8 and 11 were converters.
C. Fournier et al. / Neurobiology of Aging 74 (2019) 234.e1e234.e8234.e5et al., 2013; Majounie et al., 2012). We recently showed that genetic
factors significantly influence the AO in C9orf72 families (Barbier
et al., 2017). However, modifiers of AO in C9orf72 FTD remain not
yet fully understood, and the search for genetic factors or markers
predicting the disease outcome has become a priority to improve
patients’ genetic counseling and set up clinical trials.
Because of the particular nature of the mutation, C9orf72 FTD
and/or ALS belong to the family of repeat expansion diseases. As
observed in other repeat expansion disorders, such as Huntington’
disease or Fragile-X syndrome, it has been proposed that the size of
expansion could influence clinical features in C9orf72 disease. Es-
timate of repeats number from blood DNA has appeared as a po-
tential noninvasive biomarker, despite the fact that blood estimates
of repeats number may not exactly reflect what is occurring in the
brain (van Blitterswijk et al., 2013). Consequently, some studies
focusing on C9orf72 expansion size in peripheral lymphocytes were
performed, leading to controversial conclusions (Table 2) (Beck
et al., 2013; Cruts et al., 2013; Dols-Icardo et al., 2014; Gijselinck
et al., 2016; Nordin et al., 2015; Russ et al., 2015; Suh et al., 2015; van
Blitterswijk et al., 2013). Here, we found a positive correlation be-
tween repeats number and AO in a large cohort of 73 C9orf72 pa-
tients carrying long expansions, which is the largest cohort of
carriers in whom blood expansion repeats number was measured
to date.
A significant correlation between repeats number in blood and
AO was found in 3 previous studies, based on smaller cohorts (vanFig. 4. C9orf72 G4C2 repeats number in parent-offspring pairs. Gender of transmitting paren
carriers in the right panel. Multiple offspring are ordered according to their date of birth (#Blitterswijk et al., 2013; Nordin et al., 2015; Dols-Icardo et al., 2014).
By contrast, an inverse correlation was evidenced in a Belgian
cohort study that compared a group of 6 short expansion (<100
repeats) to 66 long expansion (>100 repeats) carriers (Gijselinck
et al., 2016; Van Mossevelde et al., 2017). However, the methodol-
ogy used in the Belgian cohort is distinct from other studies and
ours, all studying AO as a quantitative trait in long expansion car-
riers. Small samples sizes, or potential distinct mechanisms in short
and large expansion carriers, could explain divergent results. Also,
these results suggest that C9orf72 pathogenesis could depend on
crossing a repeat length, though it is unclear whether this inter-
pretation holds in brain and other disease-relevant tissues.
Despite diverging conclusions on relations between repeats
number and AO in the literature, converging evidences came out
from association analyses of C9orf72 repeats number and DNA
methylation state. Repeats expansion number has been showed to
influence DNA methylation at the C9orf72 locus, longer expansions
being associated with a higher methylation state in the 50 regula-
tory region of the gene (Gijselinck et al., 2016; Russ et al., 2015; Xi
et al., 2013). In this context, at least for longer expansions, down-
regulation of expression of the expanded C9orf72 allele might
counterbalance deleterious effects of the pathogenic expansion and
slightly delay the disease onset.
However, and besides correlations with AO, we also detected a
significant correlation between repeats number and age at collec-
tion in patients. Intriguingly, a very similar correlationwas found int, age at collection and age at onset are indicated for patients or presymptomatic (PS)
1 being the oldest). M: male, F: female.
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C. Fournier et al. / Neurobiology of Aging 74 (2019) 234.e1e234.e8 234.e6our series of 52 PS carriers with an age at collection ranging from 20
years to 88 years, which is presently the cohort covering the most
expanded range of age to look at relationship between expansion
size and age at collection. This suggests that age at collection could
be amajor confounding variable, and that the observed correlations
and associations are driven mostly by the age at collection. Indeed,
when repeats number were adjusted for the age at collection, no
significant result was observed from the analyses of correlation
with AO, nor association with clinical phenotypes. Notably, these
results are in line with those of Suh et al. who found a positive
correlation between repeats number in blood and age at collection
in C9orf72 patients, but not with age at onset after corrections for
the age at collection and disease phenotypes (Suh et al., 2015).
Finally, the collinearity between AO and age at collection prevents
to determine statistically which variable, AO or age at collection, is
driving the correlation with repeats number. This constitutes a
limitation of this work as of other studies.
To go further, we focused on PS carriers with the youngest age at
collection (45 years) and patients who developed disease before
the same age limit. Means of repeats number were not statistically
significant between these young PS carriers and patients with a
very early onset. Nevertheless, and assuming the hypothesis that
low repeats number may be associated with earlier AO in our
cohort of patients, all these young PS carriers (62% of the PS cohort)
should be at high risk to develop disease in a very short time as they
carry a number of repeats similar from the subset of patients who
converted within the same range of age. However, the age-related
penetrance before 45 years of age was previously estimated to be
lower than 10% in 2 different cohorts of C9orf72 carriers (Le Ber
et al., 2013; Majounie et al., 2012). All together, these results sug-
gest that the lower number of repeats are more likely related to a
younger age at collection rather than to the risk to develop disease,
arguing in favor of a predominant influence of the age at collection
on blood DNA repeats number estimates.
Given the correlation of the expansion size in blood with age at
collection, and due to the dynamic nature of this mutation, it is
reasonable to speculate that C9orf72 pathogenic expansions could
evolve, expand or contract, with time in a given carrier. Data from
C9orf72 individuals with multiple time points (with a mean time
interval of 57.9 months) allowed to measure blood repeats number
changes with time per patient, with a maximum time interval of
11 years. Importantly, we did not detect massive expansion or
contraction of the expansion size with time, even in carriers with
the longest follow-up interval (>10 years), or in the 2 carriers who
converted between the first and last blood samples. The repeats
number slightly varied over time in all cases. In addition, there was
no clear and concordant trend toward expansion or contraction
between first and last collections, as some carriers presented ex-
pansions, contractions, or even similar number of repeats over time.
Smaller and more subtle changes might have happened in the in-
terval between several samplings that cannot be precisely detected
because of technical limitations of the Southern blot. Indeed, long
expansions usually appear as a smear, preventing an accurate
estimation of modal number of repeats but, up to now, this is the
only method to size C9orf72 long expansions. The maximum dif-
ference due to the technical imprecision between 2 measures from
the same individual’s DNA was up to 172 repeats. According to the
slope of the regression lines between repeats number and age at
collection, number of G4C2 repeats measured in blood DNA should
increase by around 18 repeats per year. Theoretically, a longer
period of follow-up (at least 20 years) should be needed therefore
to reliably detect evolution of repeats number over time. So, in this
study, the time intervals between multiple sample collections
might have been too short to clearly observe the influence of the
age on blood repeats number with this method. The weak
C. Fournier et al. / Neurobiology of Aging 74 (2019) 234.e1e234.e8234.e7variations of observed repeats numbers more likely reflect the in-
accuracy of the measurement method rather than true variations.
Young PS C9orf72 carriers, who will be followed for a longer period
of time, should bringmore valuable data to analyze the dynamics of
the pathogenic expansion during lifespan and confirm, or not,
whether blood repeats number increases over time.
Finally, the dynamic of long expansions through generations
was investigated in 16 parent-offspring pairs. Important and
measurable changes in repeats number have been observed,
regardless of the gender or the age of transmitting parent. Unex-
pectedly, a contraction between successive generations was
observed in the majority of transmissions (11/16). It is likely that a
younger age at collection in offspring versus parents (mean differ-
ence of age at collection ¼ 28 years) may partly explain this trend
even though this hypothesis did not fit with all paired comparisons.
Indeed, expansion or stable repeat number was observed as well,
although less frequently. In line with these results, expansions as
well as contractions of C9orf72 repeats have been previously re-
ported in lymphocytes from parent-offspring pairs carrying short
expansions (Gijselinck et al., 2016; Van Mossevelde et al., 2017).
Importantly, these results demonstrate that blood C9orf72 long
expansions do not systematically expand through generations and
would argue against an anticipation phenomenon at the molecular
level.
5. Conclusions
This study establishes that long repeat expansions are highly
instable in lymphocytes and variable across time and generations.
We observed that the C9orf72 expansion size in blood correlated
with age of disease onset and moderately with clinical outcome.
However, the age at sampling appeared as a major confounding
factor, which could contribute to the observed trends. The corre-
lation between repeats number and age at collection in PS in-
dividuals including young carriers who are likely to be more distant
from the disease onset argues in favor of the last hypothesis. This
study thus clearly supports that blood measure of long repeats
cannot serve as a reliable noninvasive biomarker to predict disease
onset or evolution toward FTD or ALS in C9orf72 disease, conversely
to several other repeat expansion diseases. The identification of
alternative biomarkers, easily measurable in accessible fluids, must
therefore be a major research challenge as therapeutic era is
coming.
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